----item----
version: 1
id: {CAA18B37-810F-4A1D-86B0-86FD3E76CE67}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/04/24/GW Pharma raising $180m
parent: {AA6F50D5-126C-48B5-BD02-B1AAD79EE996}
name: GW Pharma raising $180m
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: c130e483-7e0e-450f-8ee9-3e6d8bd28acc

----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 38

{1D288E18-BAFF-4498-B284-EF9BC8D32E30}
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 23

GW Pharma raising $180m
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 23

GW Pharma raising $180m
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1801

<p>GW Pharmaceuticals, which develops therapeutics using its cannabinoid product platform, is raising $179.2m through the placement of 1,600,000 American Depositary Shares (ADSs), priced at $112per ADS on the Nasdaq Global Market. </p><p>GW has granted the underwriters a 30-day option to purchase up to an additional 240,000 ADSs at the public offering price less the underwriting discount. The offering is expected to close 5 May. Morgan Stanley, Bank of America Merrill Lynch and Cowen and Company are acting as joint book-running managers for the offering. Piper Jaffray & Co is acting as lead manager.</p><p>In an SEC filing dated 27 April, GW Pharma said it would use the proceeds of the offering for the following activities: </p><ul><li>approximately $30m to fund further expansion of our Epidiolex (cannabidiol [CBD]) manufacturing capability and build-up of inventory in preparation for US launch, if Epidiolex is approved;</li><li>approximately $30m to fund clinical development of other orphan indication opportunities for Epidiolex, with an initial focus on TSC;</li><li>approximately $30m to fund the advancement of other pipeline opportunities, including an intravenous CBD formulation in the treatment of NHIE;</li><li>approximately $40m to fund pre-launch commercialization activities for Epidiolex in the US; and</li><li>$11.5m for other general corporate purposes.</li></ul><p>Epidiolex is being developed as a treatment for Dravet syndrome (currently in Phase III), lennox-gastaut syndrome (a form of epilepsy; Phase III) and tuberous sclerosis complex (preclinical). In <a href="http://www.scripintelligence.com/business/GW-cashes-in-on-Epidiolex-data-with-148m-public-offering-352429?refid=RSSLATEST" target="_new">June 2014</a>, GW Pharma raised $148m in a public offering. </p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 235

<p>GW Pharmaceuticals, which develops therapeutics using its cannabinoid product platform, is raising $179.2m through the placement of 1,600,000 American Depositary Shares (ADSs), priced at $112per ADS on the Nasdaq Global Market. </p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 23

GW Pharma raising $180m
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150424T045335
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150424T045335
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150424T045335
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC028587
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 23

GW Pharma raising $180m
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{090E9A04-9B4B-4986-8BAF-06A6B07B978D}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 4

News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

358042
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042336Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

c130e483-7e0e-450f-8ee9-3e6d8bd28acc
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042336Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
